Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Markers for CYP3A4 DDI Prediction
NCT02975037Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASP-001 in erectile dysfunction (ED) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Quantification of endogenous metabolites (plasma) and Quantification of endogenous metabolites (urine). Started Feb 2017; status: completed.
02
Drugs
ASP-001
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT02975037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975037.